Most advanced is the recruitment of innate immunity to kill myeloma cells by monoclonal antibodies targeting antigens either aberrantly expressed on myeloma cells (e.g. SLAMF7 -elotuzumab [5]) or expressed on both, normal as well as malignant plasma cells (e.g. CD38 -daratumumab [6], isatuximab [7]). This evidence concerns the gene CD38 and plasma cell myeloma.